Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?

Vincenzo Graziano, Maria Teresa Scognamiglio, Marinella Zilli, Jamara Giampietro, Patrizia Vici, Clara Natoli, Antonino Grassadonia

Research output: Contribution to journalArticlepeer-review

Abstract

The occurrence of skin metastases is a common event in patients affected by advanced breast cancer, usually associated with systemic disease progression. Here we describe 2 cases of diffuse cutaneous metastases from HER2-overexpressing breast cancer occurring despite a dramatic response in liver and bone, respectively, during treatment with anti-HER2 antibodies Trastuzumab and Pertuzumab. We discuss the reasons for this discrepancy and suggest a possible implication of impaired immune response in the skin. Future research should provide strategies to overcome the induction of immune privilege in the skin in order to avoid discontinuation of effective treatments.

Original languageEnglish
Pages (from-to)1704-1709
Number of pages6
JournalCancer Biology and Therapy
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 2 2015

Keywords

  • breast cancer
  • immune privilege
  • immune response
  • immune tolerance
  • pertuzumab
  • skin metastases
  • trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Fingerprint

Dive into the research topics of 'Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?'. Together they form a unique fingerprint.

Cite this